FIELD: virology; medicine.
SUBSTANCE: invention relates to a compound having high antiviral activity of anti-SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2, formerly 2019-nCoV). Disclosed is the use of a water-soluble dihydrochloride compound of 6-bromo-1-methyl-5-methoxy-2-(1-piperidinomethyl)-3-(2-diethylaminoethoxy)carbonylindole of general formula (II), having in vitro dose-dependent activity on SARS-CoV-2, which at concentration of 30 mcg/ml completely inhibits coronavirus infection SARS-CoV-2. Compound II has IFN-inducing activity and inhibits syncytium formation mediated by the spinous protein (S-glycoprotein) SARS-CoV-2, and also has high activity (IC50=1.06 mcg/ml) and selectivity (selectivity index SI=78.6).
EFFECT: using the invention enables to effectively suppress the reproduction of SARS-CoV-2.
1 cl, 1 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDOLE-3-CARBOXYLIC ACID DERIVATIVES HAVING ANTIVIRAL ACTIVITY | 2013 |
|
RU2552422C2 |
| STRAIN OF HYBRID ANIMAL CELLS MUS MUSCULUS 2E1B5 - PRODUCER OF A MONOCLONAL ANTIBODY AGAINST THE RECEPROT-BINDING DOMAIN OF PROTEIN S OF THE SARS-CoV-2 VIRUS | 2021 |
|
RU2771288C1 |
| INDOL-3-CARBOXIC ACID DERIVATIVES WITH ANTI-TUMOR ACTIVITY | 2022 |
|
RU2782931C2 |
| 5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE AND ITS APPLICATION | 2022 |
|
RU2791523C1 |
| METHOD FOR OBTAINING 5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE | 2022 |
|
RU2791916C1 |
| URACIL DERIVATIVES WITH ANTIVIRAL ACTIVITY AGAINST SARS-COV-2 | 2021 |
|
RU2769828C1 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| STRAIN OF HYBRID ANIMAL CELLS Mus MUSCULUS 1F1 - PRODUCER OF A MONOCLONAL ANTIBODY AGAINST THE NUCLEOCAPSID PROTEIN N OF THE SARS-CoV-2 VIRUS | 2021 |
|
RU2769817C1 |
| SARS-COV-2 REPLICATION INHIBITOR BASED ON A WATER EXTRACT OF THE FUNGUS INONOTUS OBLIQUUS | 2020 |
|
RU2741714C1 |
| ANTIVIRAL AGENT | 2014 |
|
RU2564919C1 |
